For research use only. Not for therapeutic Use.
NNZ-2591（Cat No.:I042645）is an investigational synthetic analog of cyclic glycine-proline (cGP), developed by Neuren Pharmaceuticals, targeting neurodevelopmental disorders such as Angelman syndrome, Phelan-McDermid syndrome (PMS), Pitt Hopkins syndrome, and Prader-Willi syndrome. Preclinical studies have demonstrated its neuroprotective properties, including improved motor function in Parkinson’s disease models and cognitive enhancement in memory impairment models. In December 2023, a Phase 2 clinical trial in children with PMS showed significant improvements across multiple efficacy measures, with NNZ-2591 being well-tolerated and exhibiting a favorable safety profile. The U.S. FDA has granted NNZ-2591 Orphan Drug designation for the treatment of Angelman syndrome, PMS, and Pitt Hopkins syndrome.
| CAS Number | 847952-38-9 |
| Synonyms | (8aR)-8a-prop-2-enyl-3,6,7,8-tetrahydro-2H-pyrrolo[1,2-a]pyrazine-1,4-dione |
| Molecular Formula | C10H14N2O2 |
| Purity | ≥95% |
| IUPAC Name | (8aR)-8a-prop-2-enyl-3,6,7,8-tetrahydro-2H-pyrrolo[1,2-a]pyrazine-1,4-dione |
| InChI | InChI=1S/C10H14N2O2/c1-2-4-10-5-3-6-12(10)8(13)7-11-9(10)14/h2H,1,3-7H2,(H,11,14)/t10-/m0/s1 |
| InChIKey | WVKCGUOWPZAROG-JTQLQIEISA-N |
| SMILES | C=CC[C@@]12CCCN1C(=O)CNC2=O |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
